{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T09:44:50Z","timestamp":1794217490410,"version":"4.8.0"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010527","name":"Public Health Scotland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010527","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018336","name":"National Institute for Health Research Health Protection Research Unit","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100024721","name":"Public Health Scotland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024721","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007602","name":"National Institute for Health Research Programme Grants for Applied Research","doi-asserted-by":"publisher","award":["RP-PG-0616-20008"],"award-info":[{"award-number":["RP-PG-0616-20008"]}],"id":[{"id":"10.13039\/501100007602","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Regional Health - Europe"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.lanepe.2025.101505","type":"journal-article","created":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T22:25:03Z","timestamp":1761690303000},"page":"101505","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Estimating incidence rates of primary infection and reinfection with hepatitis C virus among people who inject drugs in Scotland: a model-based analysis of repeated cross-sectional survey data"],"prefix":"10.1016","volume":"60","author":[{"given":"Scott A.","family":"McDonald","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norah","family":"Palmateer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"McAuley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rory N.","family":"Gunson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0415-785X","authenticated-orcid":false,"given":"Stephen T.","family":"Barclay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F.","family":"Dillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9864-459X","authenticated-orcid":false,"given":"Matthew","family":"Hickman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6891-6758","authenticated-orcid":false,"given":"Sharon J.","family":"Hutchinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lanepe.2025.101505_bib1","series-title":"Global hepatitis report 2024: action for access in low- and middle-income countries","year":"2024"},{"issue":"1","key":"10.1016\/j.lanepe.2025.101505_bib2","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s12889-022-14911-1","article-title":"Laying the foundations for hepatitis C elimination: evaluating the development and contribution of community care pathways to diagnostic efforts","volume":"23","author":"Robinson","year":"2023","journal-title":"BMC Public Health"},{"key":"10.1016\/j.lanepe.2025.101505_bib3","series-title":"Global health sector strategy on viral hepatitis 2016\u20132021: towards ending viral hepatitis","year":"2016"},{"key":"10.1016\/j.lanepe.2025.101505_bib4","series-title":"Scotland's hepatitis C action plan: achievements of the first decade and proposals for a Scottish government strategy (2019) for the elimination of both infection and disease","author":"Goldberg","year":"2019"},{"key":"10.1016\/j.lanepe.2025.101505_bib5","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-029538","article-title":"Evaluating the population impact of hepatitis C direct acting antiviral treatment as prevention for people who inject drugs (EPIToPe): a natural experiment (protocol)","volume":"9","author":"Hickman","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.lanepe.2025.101505_bib6","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S2468-1253(19)30085-8","article-title":"The contribution of injection drug use to hepatitis C virus transmission globally, regionally, and at country level: a modelling study","volume":"4","author":"Trickey","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10","key":"10.1016\/j.lanepe.2025.101505_bib7","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1111\/add.15459","article-title":"Reduction in the population prevalence of hepatitis C virus viraemia among people who inject drugs associated with scale-up of direct-acting anti-viral therapy in community drug services: real-world data","volume":"116","author":"Palmateer","year":"2021","journal-title":"Addiction"},{"key":"10.1016\/j.lanepe.2025.101505_bib8","article-title":"Evaluating the effect of direct-acting antiviral agent treatment scale-up on hepatitis C virus prevalence among people who inject drugs in UK","volume":"144","author":"Samartsidis","year":"2024","journal-title":"Int J Drug Policy"},{"key":"10.1016\/j.lanepe.2025.101505_bib9","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jhep.2018.09.030","article-title":"Association between rapid utilisation of direct hepatitis C antivirals and decline in the prevalence of viremia among people who inject drugs in Australia","volume":"70","author":"Iversen","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.lanepe.2025.101505_bib10","series-title":"Major reduction in the population prevalence of chronic hepatitis C virus (HCV) among people who inject drugs associated with scale-up of direct-acting antiviral therapy in Scotland: evidence on HCV elimination targets","author":"Palmateer","year":"2024"},{"key":"10.1016\/j.lanepe.2025.101505_bib11","article-title":"Impact and cost-effectiveness of scaling up HCV testing and treatment strategies for achieving HCV elimination among people who inject drugs in England: a mathematical modelling study","volume":"49","author":"Ward","year":"2025","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.lanepe.2025.101505_bib12","year":"2024"},{"issue":"4","key":"10.1016\/j.lanepe.2025.101505_bib13","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S2468-1253(21)00311-3","article-title":"Methods and indicators to validate country reductions in incidence of hepatitis C virus infection to elimination levels set by WHO","volume":"7","author":"Artenie","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"30","key":"10.1016\/j.lanepe.2025.101505_bib14","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2023.28.30.2200952","article-title":"Insights from a national survey in 2021 and from modelling on progress towards hepatitis C virus elimination in the country of Georgia since 2015","volume":"28","author":"Walker","year":"2023","journal-title":"Eurosurv"},{"key":"10.1016\/j.lanepe.2025.101505_bib15","year":"2022"},{"issue":"7","key":"10.1016\/j.lanepe.2025.101505_bib17","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1111\/add.16169","article-title":"Improved health-related quality of life after hepatitis C viraemic clearance among people who inject drugs may not be durable","volume":"118","author":"McDonald","year":"2023","journal-title":"Addiction"},{"issue":"8","key":"10.1016\/j.lanepe.2025.101505_bib18","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1111\/add.16500","article-title":"Prevalence of opioid dependence in Scotland 2015\u20132020: a multi-parameter estimation of prevalence (MPEP) study","volume":"119","author":"Markoulidakis","year":"2024","journal-title":"Addiction"},{"key":"10.1016\/j.lanepe.2025.101505_bib19","series-title":"JAGS: a program for analysis of bayesian graphical models using gibbs sampling","author":"Plummer","year":"2003"},{"issue":"6","key":"10.1016\/j.lanepe.2025.101505_bib20","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/hiv.12602","article-title":"Rapid decline of anti-hepatitis C virus (HCV) antibodies following early treatment of incident HCV infections in HIV-infected men who have sex with men","volume":"19","author":"Aebi-Popp","year":"2018","journal-title":"HIV Med"},{"key":"10.1016\/j.lanepe.2025.101505_bib21","article-title":"Utilising integrated bio-behavioural surveillance (IBBS) to investigate declining hepatitis C antibody prevalence among people who inject drugs in the Australian needle and syringe program survey","volume":"144","author":"Maher","year":"2024","journal-title":"Int J Drug Policy"},{"key":"10.1016\/j.lanepe.2025.101505_bib22","series-title":"R: a language and environment for statistical computing","year":"2023"},{"issue":"6","key":"10.1016\/j.lanepe.2025.101505_bib23","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S2468-1253(23)00018-3","article-title":"HIV and HCV incidence review collaborative group. Incidence of HIV and hepatitis C virus among people who inject drugs, and associations with age and sex or gender: a global systematic review and meta-analysis","volume":"8","author":"Artenie","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.lanepe.2025.101505_bib24","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S2468-1253(24)00442-4","article-title":"Global, regional, and national estimates of hepatitis C virus (HCV) infection incidence among people who inject drugs and number of new annual HCV infections attributable to injecting drug use: a multi-stage analysis","volume":"10","author":"Artenie","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"}],"container-title":["The Lancet Regional Health - Europe"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666776225002972?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666776225002972?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T23:24:35Z","timestamp":1773271475000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666776225002972"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":23,"alternative-id":["S2666776225002972"],"URL":"https:\/\/doi.org\/10.1016\/j.lanepe.2025.101505","relation":{},"ISSN":["2666-7762"],"issn-type":[{"value":"2666-7762","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Estimating incidence rates of primary infection and reinfection with hepatitis C virus among people who inject drugs in Scotland: a model-based analysis of repeated cross-sectional survey data","name":"articletitle","label":"Article Title"},{"value":"The Lancet Regional Health - Europe","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lanepe.2025.101505","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101505"}}